Jabryus 100Mg 4 Blisters Of 7 Tablets

JABRYUS 100MG 4 BLISTERS OF 7 TABLETS may interact with the following medicines:

• Antihypertensive medicines (e.g., amlodipine, atenolol): Patients with cardiovascular risk factors taking multiple medicines may require careful monitoring during treatment because JAK inhibitors may increase the risk of major cardiovascular events in susceptible individuals.
• Antidiabetic medicines (e.g., insulin, metformin): Patients with diabetes may have a higher risk of infections during treatment. Your doctor may monitor blood sugar levels and infection-related symptoms during therapy.
• Antitubercular medicines (e.g., rifampicin, rifabutin): These medicines may reduce abrocitinib levels and decrease treatment effectiveness. Your doctor may avoid this combination or monitor treatment response carefully.
• Antiepileptic medicines (e.g., phenytoin, carbamazepine): These medicines may increase breakdown of abrocitinib and reduce its effectiveness. Your doctor may monitor eczema symptom control during combined therapy.
• Immunosuppressant medicines (e.g., ciclosporin, tacrolimus): Taking these medicines together may increase the risk of serious infections and immune-related complications. Combined use is generally not recommended.
• Antiplatelet medicines (e.g., clopidogrel, ticagrelor): Taking these medicines together may increase the risk of bleeding-related complications and thrombocytopenia during treatment. Your doctor may avoid or closely monitor such combinations.

JABRYUS 100MG 4 BLISTERS OF 7 TABLETS may interact with the following:

• Grapefruit and grapefruit juice: Grapefruit and grapefruit juice may increase abrocitinib levels in the body and increase the risk of side effects such as nausea, dizziness, headache, infections, or blood-related abnormalities during treatment. It is advisable to avoid grapefruit and grapefruit juice while taking JABRYUS 100MG 4 BLISTERS OF 7 TABLETS.

JABRYUS 100MG 4 BLISTERS OF 7 TABLETS should be used with caution if you have:

• Active infections: This medicine may weaken immune response and increase the risk of serious bacterial, viral, fungal, or opportunistic infections. Your doctor may delay treatment until infections are controlled.
• Tuberculosis: Patients with active or latent tuberculosis may experience worsening infection during treatment. Tuberculosis screening is recommended before starting therapy.
• Blood clotting disorders: JAK inhibitors may increase the risk of deep vein thrombosis, pulmonary embolism, or arterial thrombosis in susceptible individuals. Your doctor may evaluate clotting risk before and during treatment.
• Heart disease or cardiovascular risk factors: Patients with cardiovascular disease, smoking history, or stroke risk may have an increased risk of major cardiovascular events during treatment. Your doctor may monitor cardiovascular health closely.
• Cancer or history of malignancy: JAK inhibitors may increase the risk of certain cancers in susceptible individuals. Your doctor may evaluate treatment suitability carefully in patients with a history of malignancy.

Take JABRYUS 100MG 4 BLISTERS OF 7 TABLETS exactly as prescribed by your doctor. The dosage may vary depending on the severity of atopic dermatitis, age, kidney function, medical history, and response to treatment. Your doctor may adjust the treatment based on symptom control and tolerance. Do not stop treatment or change the prescribed schedule without consulting your doctor.

Taking more than the prescribed amount of JABRYUS 100MG 4 BLISTERS OF 7 TABLETS may increase the risk of severe nausea, dizziness, infections, blood-related abnormalities, or immune-related complications. Seek immediate medical attention if overdose is suspected.

If you miss a dose of JABRYUS 100MG 4 BLISTERS OF 7 TABLETS, take it as soon as you remember unless it is less than 12 hours before your next scheduled dose. Skip the missed dose if the next dose is due soon. Do not take double doses to compensate for the missed dose.